Bourdy Geneviève, Aubertin Catherine, Jullian Valérie, Deharo Eric
UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, France.
UMR 208 Patrimoines locaux et gouvernance, Institut de recherche pour le développement/Muséum national d'Histoire naturelle, 57 rue Cuvier - CP 51 75231, Paris cedex 05, France.
J Ethnopharmacol. 2017 Jul 12;206:290-297. doi: 10.1016/j.jep.2017.05.030. Epub 2017 May 31.
Biopiracy accusations are common in the world of biodiversity research. At the end of 2015, a French NGO accused researchers from the Institut de Recherche pour le Développement (IRD) of biopiracy. These researchers had applied for a patent for a natural bioactive molecule against malaria and cancer, the Simalikalactone E, isolated from Quassia amara L. (Simaroubaceae) leaves. This biopiracy allegation triggered a huge wave of attacks from the media and social networks, and vehement recrimination from political officials in French Guiana against researchers who have been accused of ethical misconduct, by stealing the traditional knowledge of indigenous people. These accusations were made in the contentious context of the ratification of the Nagoya Protocol in the frame of implementing the French law on biodiversity, nature and landscapes. So, in an atmosphere of heightened emotions it is crucial to understand the issues behind these accusations. We describe herein the genesis of our discovery, present the detractors' arguments, and discuss the consequences of such biopiracy denunciations for scientific research. We also address our concerns about the gap between rhetoric and reality and the real impact of the Nagoya Protocol on biodiversity conservation.
生物剽窃指控在生物多样性研究领域屡见不鲜。2015年末,一家法国非政府组织指控法国发展研究所(IRD)的研究人员存在生物剽窃行为。这些研究人员曾申请一项针对疟疾和癌症的天然生物活性分子——从苦木科苦木属植物苦木叶中分离出的西马卡内酯E的专利。这起生物剽窃指控引发了媒体和社交网络的巨大抨击浪潮,法属圭亚那的政治官员也对被指控存在道德失范行为、窃取原住民传统知识的研究人员进行了激烈指责。这些指控是在法国批准《名古屋议定书》以实施其生物多样性、自然和景观相关法律的有争议背景下提出的。因此,在情绪高涨的氛围中,理解这些指控背后的问题至关重要。我们在此描述我们发现的起源,呈现诋毁者的论点,并讨论此类生物剽窃指控对科学研究的影响。我们还阐述了我们对言辞与现实差距以及《名古屋议定书》对生物多样性保护实际影响的担忧。